![List of the 150 largest Oncology Venture Capital Investors [Update 2024]](https://www.thousandinvestors.com/wp-content/uploads/2022/11/Thousand-Investors-Oncology.png)
This article directly stems from the research process for our global venture capital investors database. Based on this list and our advanced keyword crawler technology, we created a list of venture capital investors that mention oncology-related keywords on their website. The list – offered as an Excel file – is perfectly suited to get in touch with the most relevant investors in the field.
This article highlights three significant oncology venture capital investment funds in Europe from our keyword crawler generated oncology VC investor list.
1. Kurma Partners (France)
Kurma Partners funds various stages of company maturity, from creation and early-stage to capital expansion. Their goal is to invest in the healthcare sector, ranging from cutting-edge medicines to medical devices and treatments for patients with severe illnesses. Since 2009 Kurma Partners has financed 60 companies, including Tacalyx. To date, there is no satisfactory treatment for metastatic malignant tumours. Tacalyx is developing therapeutics that target cancer-specific carbohydrate antigens to combat this issue.
2. Ysios Capital (Spain)
Ysios Capital aims to support companies with resources to develop new treatments for illnesses with high unmet medical needs. Therefore, they fund projects that impact patients positively. Ysios has invested over 1000 Million euros in therapeutic research and development and has brought 14 medical products from lab to market. Inbiomotion is part of their portfolio and is a Barcelona-based medicine company that develops biomarkers that predict bone metastasis. This should improve cancer patient’s quality of life.
3. Claris Ventures (Italy)
Claris Ventures is a venture capital investor from Italy that funds early-stage biopharma companies. Their goal is to address unmet clinical needs and are committed to support innovators with a clear vision and scientific evidence. Their portfolio, among others, consist of NeoPhore, a medicinal project targeting the cancer neoantigen evolution and Resalis Therpeutics, a company developing anti-miR compounds to fight cancer using a multi-pathway approach.
Picture Source: National Cancer Institute
